

Regimen Reference Order – MYEL - RVD

ARIA: MYEL – [RVD]

Planned Course: Every 28 days for 4 cycles

Indication for Use: Multiple Myeloma

CVAD: At Provider's Discretion

Proceed with treatment if:

ANC equal to or greater than $1 \times 10^9/L$ AND Platelets equal to or greater than $30 \times 10^9/L$

❖ Contact Physician if parameters not met

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – MYEL - RVD

Drug	Dose	CCMB Administration Guideline
dexamethasone	40 mg	Orally once daily on Days 1, 8, 15 and 22 (self-administered at home)
bortezomib	1.5 mg/m ²	Subcutaneous injection once weekly on Days 1, 8, 15 and 22
lenalidomide	25 mg	Orally once daily on Days 1 to 21. Can be taken any time of day (self-administered at home)
lenalidomide (Revlimid®) available dosage strengths: 5 mg, 10 mg, 15 mg, 20 mg and 25 mg capsules		
Classification: Cytotoxic, Hazardous		

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

Prior to all Cycles

- CBC, retic, creatinine, calcium, albumin, random glucose, LFTs, and SPEP/FLCI (response assessment) as per physician order

Day 15 (cycles 1 and 2 only)

- CBC

Every 3 months

- TSH, HbA1C

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
acetylsalicylic acid (ASA) enteric coated	81 mg delayed release	Orally once daily
valACYclovir	500 mg	Orally once daily
metoclopramide	10 -20 mg	Orally every 4 to 6 hours as needed for nausea and vomiting

DISCHARGE INSTRUCTIONS

- Instruct patient to continue taking anti-emetic(s) at home
- Advise patient to avoid green tea to prevent interactions with bortezomib
- Remind patient to take lenalidomide and dexamethasone at home
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- All patients should be considered for bisphosphonate therapy
- lenalidomide is teratogenic
- Female patients of childbearing potential will require monthly pregnancy tests (β HCG) that must be done within 7 days of the next prescription fill
- lenalidomide is controlled by a distribution program requiring prescriptions to be written by a RevAid registered physician and dispensed by a RevAid registered pharmacy